BridGene Biosciences Inc.
BridGene Biosciences is a biotechnology company focused on discovering and developing innovative small molecules to target high-value yet previously undruggable proteins, aiming to create new therapies for diseases. They utilize their proprietary IMTAC™ platform, which enables proteome-wide screening in live cells to identify drug candidates for challenging targets. Their mission is to expand small molecule drug discovery approaches rapidly and successfully.
Industries
Nr. of Employees
small (1-50)
BridGene Biosciences Inc.
Sunnyvale, California, United States, North America
Products
Clinical‑stage TEAD pathway inhibitor candidate
A small‑molecule inhibitor targeting the TEAD pathway that progressed through preclinical development, had an IND accepted by regulatory authorities and entered a Phase I dosing study in advanced solid tumors.
Clinical‑stage TEAD pathway inhibitor candidate
A small‑molecule inhibitor targeting the TEAD pathway that progressed through preclinical development, had an IND accepted by regulatory authorities and entered a Phase I dosing study in advanced solid tumors.
Services
Platform access and collaborative research agreements
Licensing or collaborative research providing access to the chemoproteomics screening platform for target discovery and lead identification under program‑based agreements with milestone/royalty structures.
Live‑cell proteome‑wide and target‑focused screening services
Contract screening services using live‑cell chemoproteomic workflows and quantitative MS to identify protein binders, quantify relative affinity, and deconvolute phenotypic hits.
Platform access and collaborative research agreements
Licensing or collaborative research providing access to the chemoproteomics screening platform for target discovery and lead identification under program‑based agreements with milestone/royalty structures.
Live‑cell proteome‑wide and target‑focused screening services
Contract screening services using live‑cell chemoproteomic workflows and quantitative MS to identify protein binders, quantify relative affinity, and deconvolute phenotypic hits.
Expertise Areas
- Chemoproteomics‑driven target identification
- Small‑molecule discovery for previously undruggable targets
- Covalent ligand discovery and library design
- Live‑cell proteome‑wide and target‑focused screening
Key Technologies
- Isobaric mass‑tagged affinity characterization
- Chemoproteomics
- Quantitative mass spectrometry
- Live‑cell screening